

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/R19E96D528E3EN.html>

Date: August 2022

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: R19E96D528E3EN

Abstracts

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Retinoic Acid Receptor Gamma - Drugs In Development, 2022'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The report 'Retinoic Acid Receptor Gamma - Drugs In Development, 2022' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or

Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 2, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Gastrointestinal, Immunology, Infectious Disease, Metabolic Disorders and Oncology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Hand Dermatitis, Head And Neck Cancer, Inflammatory Bowel Disease, Kaposi Sarcoma, Keratoconjunctivitis Sicca (Dry Eye), Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Bausch Health Companies Inc

Boehringer Ingelheim International GmbH

Galephar Pharmaceutical Research Inc

Ipsen SA

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Promius Pharma LLC

Sveikatal Inc

TherapyX Inc

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles

(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(adapalene + clindamycin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

History of Events

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

bexarotene + CD-1530 - Drug Profile

Product Description

Mechanism Of Action

palovarotene - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and

Spondylosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal

Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize RARG for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

tazarotene - Drug Profile

Product Description

Mechanism Of Action

History of Events

tazarotene - Drug Profile

Product Description

Mechanism Of Action

History of Events

tretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

tretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

trifarotene - Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

History of Events

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones

Featured News & Press Releases

Jun 29, 2022: Ipsen announces U.S. FDA priority review for palovarotene new drug application in patients with fibrodysplasia ossificans progressiva following resubmission

Mar 22, 2022: Ortho Dermatologics will present new data on IDP-126 Gel at the 2022 American Academy of Dermatology Annual Meeting

Jan 24, 2022: Health Canada approves Ipsen's Sohonos (palovarotene capsules) as the first approved treatment for Fibrodysplasia Ossificans Progressiva

Oct 28, 2021: The first and only tazarotene lotion indicated for acne vulgaris in patients 10 years of age and older, ARAZLO now available for patients by prescription across Canada

Oct 19, 2021: Ortho Dermatologics to present new data on ARAZLO at the 2021 Fall Clinical Dermatology Conference

Sep 13, 2021: Voluntary announcement Adapalene Clindamycin Hydrochloride combination gel passing the on site inspection for drug registration in China becoming the third GMP inspection that the company has passed this year

Aug 13, 2021: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris

May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Apr 22, 2021: Ortho Dermatologics announces statistically significant topline results from second pivotal phase 3 clinical trial evaluating IDP-126 gel in acne vulgaris

Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting

Feb 24, 2021: Galderma and Aklief (trifarotene) cream, 0.005% unveil me being me campaign to inspire young people with acne to live life to the fullest

Feb 09, 2021: Lee's Pharmaceutical Holdings: Update on an investigational dermatology product

Nov 16, 2020: Trifarotene in moderate acne: no study data for the assessment of the added benefit

Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Advent Therapeutics Inc, 2022

Pipeline by Avecho Biotechnology Ltd, 2022

Pipeline by Bausch Health Companies Inc, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by Galephar Pharmaceutical Research Inc, 2022

Pipeline by Ipsen SA, 2022

Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022

Pipeline by Orphanix GmbH, 2022

Pipeline by Ortho Dermatologics Inc, 2022

Pipeline by Promius Pharma LLC, 2022

Pipeline by Sveikatal Inc, 2022

Pipeline by TherapyX Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R19E96D528E3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R19E96D528E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970